HCA Healthcare is trading higher as investors rotate back into the name following the company’s late-week Q1 update and commentary that kept full-year 2026 targets intact. The move looks like a sentiment reversal after the post-earnings drawdown, with buyers focusing on reaffirmed guidance and evidence that volumes held up better than feared in core metrics such as same-facility admissions.

In its first-quarter 2026 release, HCA reported revenue of $19.109 billion (+4.3% year over year) and diluted EPS of $7.15, with adjusted EBITDA of $3.802 billion. Same-facility admissions rose 0.9% and equivalent admissions rose 1.3%, while the company reiterated its 2026 framework (revenue $76.5B–$80.0B and EPS $29.10–$31.50), helping stabilize expectations after the initial market reaction. (s23.q4cdn.com)

Adding to today’s catalyst set, HCA disclosed a proposed offering of senior notes at the subsidiary level, with proceeds intended for general corporate purposes that may include paying down commercial paper and potentially redeeming portions of its 5.250% notes due June 2026 ($1.5B) and 5.375% notes due September 2026 ($1.0B). Traders often view this as a proactive refinancing step that can reduce near-term maturity pressure, even if final terms depend on market conditions at pricing. (businesswire.com)

Even with guidance reaffirmed, HCA continues to flag a meaningful 2026 EBITDA headwind tied to ACA exchange dynamics, including subsidy-related changes, estimated at roughly $600 million to $900 million for the year. The stock’s bounce suggests investors are more willing today to look through that drag, but it remains a central variable for forward margin expectations. (beckershospitalreview.com)